HRP20231276T1 - Inhibitor egfr-a za liječenje raka - Google Patents
Inhibitor egfr-a za liječenje raka Download PDFInfo
- Publication number
- HRP20231276T1 HRP20231276T1 HRP20231276TT HRP20231276T HRP20231276T1 HR P20231276 T1 HRP20231276 T1 HR P20231276T1 HR P20231276T T HRP20231276T T HR P20231276TT HR P20231276 T HRP20231276 T HR P20231276T HR P20231276 T1 HRP20231276 T1 HR P20231276T1
- Authority
- HR
- Croatia
- Prior art keywords
- compound
- treatment
- cancer
- formula
- egfr inhibitor
- Prior art date
Links
- 238000011282 treatment Methods 0.000 title claims 3
- 206010028980 Neoplasm Diseases 0.000 title claims 2
- 201000011510 cancer Diseases 0.000 title claims 2
- 229940121647 egfr inhibitor Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 9
- 238000011321 prophylaxis Methods 0.000 claims 2
- GETZDLDQXLFTNH-SIHBAMTISA-N C1=NC(=C2N1C[C@@H](C2)F)C(C(=O)NC1=NC=CS1)N1C=C2C(=CC(=C(C2=N1)Cl)C1=CC=C(C=C1)N1CCOCC1)Cl Chemical compound C1=NC(=C2N1C[C@@H](C2)F)C(C(=O)NC1=NC=CS1)N1C=C2C(=CC(=C(C2=N1)Cl)C1=CC=C(C=C1)N1CCOCC1)Cl GETZDLDQXLFTNH-SIHBAMTISA-N 0.000 claims 1
- 239000013543 active substance Substances 0.000 claims 1
- 208000002154 non-small cell lung carcinoma Diseases 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Claims (7)
1. Spoj, naznačen time, da je predstavljen formulom (I)
[image]
(I)
ili njegove farmaceutski prihvatljive soli.
2. Spoj formule (I) prema patentnom zahtjevu 1, naznačen time, da je spoj sljedeći
[image]
.
3. Spoj formule (I) prema patentnom zahtjevu 1 ili 2, naznačen time, da je spoj 2-[4,7-dikloro-6-(4-morfolinofenil)indazol-2-il]-2-[(6R)-6-fluoro-6,7-dihidro-5H-pirolo[1,2-c]imidazol-1-il]-N-tiazol-2-il-acetamid.
4. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za upotrebu kao terapeutski aktivna tvar.
5. Farmaceutski pripravak, naznačen time, da sadrži spoj prema bilo kojem od patentnih zahtjeva 1 do 3, i terapeutski inertni nosač.
6. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za primjenu u liječenju ili profilaksi raka.
7. Spoj prema bilo kojem od patentnih zahtjeva 1 do 3, naznačen time, da je za primjenu u liječenju ili profilaksi raka pluća nemalih stanica.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP19181754 | 2019-06-21 | ||
PCT/EP2020/067076 WO2020254562A1 (en) | 2019-06-21 | 2020-06-19 | Egfr inhibitor for the treatment of cancer |
EP20734871.5A EP3986897B1 (en) | 2019-06-21 | 2020-06-19 | Egfr inhibitor for the treatment of cancer |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20231276T1 true HRP20231276T1 (hr) | 2024-02-02 |
Family
ID=67139601
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20231276TT HRP20231276T1 (hr) | 2019-06-21 | 2020-06-19 | Inhibitor egfr-a za liječenje raka |
Country Status (28)
Country | Link |
---|---|
US (4) | US20230054473A1 (hr) |
EP (4) | EP3986895B1 (hr) |
JP (4) | JP2022537769A (hr) |
KR (1) | KR20220024105A (hr) |
CN (4) | CN113966335A (hr) |
AR (4) | AR119210A1 (hr) |
AU (1) | AU2020295703A1 (hr) |
BR (1) | BR112021025445B1 (hr) |
CA (1) | CA3140485A1 (hr) |
CL (1) | CL2021003408A1 (hr) |
CO (1) | CO2021017173A2 (hr) |
CR (1) | CR20210624A (hr) |
DK (1) | DK3986897T3 (hr) |
ES (1) | ES2961187T3 (hr) |
FI (1) | FI3986897T3 (hr) |
HR (1) | HRP20231276T1 (hr) |
HU (1) | HUE063676T2 (hr) |
IL (1) | IL288522A (hr) |
LT (1) | LT3986897T (hr) |
MA (1) | MA56508B1 (hr) |
MX (1) | MX2021015464A (hr) |
PE (1) | PE20220576A1 (hr) |
PL (1) | PL3986897T3 (hr) |
PT (1) | PT3986897T (hr) |
RS (1) | RS64720B1 (hr) |
SI (1) | SI3986897T1 (hr) |
TW (4) | TW202115071A (hr) |
WO (4) | WO2020254572A1 (hr) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023217923A1 (en) * | 2022-05-13 | 2023-11-16 | F. Hoffmann-La Roche Ag | New indazole derivatives |
WO2023217924A1 (en) * | 2022-05-13 | 2023-11-16 | F. Hoffmann-La Roche Ag | Combination of allosteric and orthosteric egfr inhibitors for the treatment of cancer |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB0508715D0 (en) * | 2005-04-29 | 2005-06-08 | Astrazeneca Ab | Chemical compounds |
CN101273033A (zh) * | 2005-09-20 | 2008-09-24 | 阿斯利康(瑞典)有限公司 | 作为治疗癌症的erbb受体酪氨酸激酶抑制剂的4-(1h-吲哚-5-基-氨基)-喹唑啉化合物 |
EP2307365B1 (en) | 2008-06-25 | 2013-03-27 | Merck Sharp & Dohme Corp. | Synthesis and use of heterocyclic antibacterial agents |
US8420661B2 (en) | 2010-04-13 | 2013-04-16 | Hoffmann-La Roche Inc. | Arylethynyl derivatives |
WO2015095807A1 (en) * | 2013-12-20 | 2015-06-25 | Biomed Valley Discoveries, Inc. | Cancer treatments using combinations of egfr and erk inhibitors |
CN105777756B (zh) * | 2014-07-02 | 2019-03-01 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
CN107108613B (zh) * | 2014-11-10 | 2020-02-25 | 基因泰克公司 | 布罗莫结构域抑制剂及其用途 |
WO2016183534A1 (en) | 2015-05-14 | 2016-11-17 | The Wistar Institute Of Anatomy And Biology | Ebna1 inhibitors and methods using same |
TW201834651A (zh) * | 2016-12-22 | 2018-10-01 | 瑞士商赫孚孟拉羅股份公司 | 化合物 |
AR113299A1 (es) * | 2017-06-02 | 2020-04-08 | Hoffmann La Roche | Compuestos de isoindolina |
WO2019046668A1 (en) * | 2017-08-31 | 2019-03-07 | Kezar Life Sciences | AMIDE-SUBSTITUTED THIAZOLES AS INHIBITORS OF SECRETIC PROTEIN |
CR20200625A (es) * | 2018-06-29 | 2021-02-05 | Hoffmann La Roche | Compuestos |
-
2020
- 2020-06-19 LT LTEPPCT/EP2020/067076T patent/LT3986897T/lt unknown
- 2020-06-19 EP EP20734160.3A patent/EP3986895B1/en active Active
- 2020-06-19 CR CR20210624A patent/CR20210624A/es unknown
- 2020-06-19 EP EP20734871.5A patent/EP3986897B1/en active Active
- 2020-06-19 SI SI202030292T patent/SI3986897T1/sl unknown
- 2020-06-19 WO PCT/EP2020/067093 patent/WO2020254572A1/en active Application Filing
- 2020-06-19 AR ARP200101749A patent/AR119210A1/es unknown
- 2020-06-19 WO PCT/EP2020/067076 patent/WO2020254562A1/en active Application Filing
- 2020-06-19 CN CN202080043708.9A patent/CN113966335A/zh active Pending
- 2020-06-19 CN CN202080045269.5A patent/CN113993873A/zh active Pending
- 2020-06-19 CA CA3140485A patent/CA3140485A1/en active Pending
- 2020-06-19 ES ES20734871T patent/ES2961187T3/es active Active
- 2020-06-19 AR ARP200101745A patent/AR119206A1/es unknown
- 2020-06-19 DK DK20734871.5T patent/DK3986897T3/da active
- 2020-06-19 RS RS20230942A patent/RS64720B1/sr unknown
- 2020-06-19 AR ARP200101748A patent/AR119209A1/es unknown
- 2020-06-19 FI FIEP20734871.5T patent/FI3986897T3/fi active
- 2020-06-19 TW TW109120781A patent/TW202115071A/zh unknown
- 2020-06-19 JP JP2021576020A patent/JP2022537769A/ja active Pending
- 2020-06-19 TW TW109120782A patent/TW202115053A/zh unknown
- 2020-06-19 BR BR112021025445-5A patent/BR112021025445B1/pt active IP Right Grant
- 2020-06-19 PT PT207348715T patent/PT3986897T/pt unknown
- 2020-06-19 US US17/620,242 patent/US20230054473A1/en active Pending
- 2020-06-19 TW TW109120783A patent/TW202115072A/zh unknown
- 2020-06-19 EP EP20734872.3A patent/EP3986898B1/en active Active
- 2020-06-19 US US17/620,240 patent/US20220315593A1/en active Pending
- 2020-06-19 KR KR1020217041612A patent/KR20220024105A/ko unknown
- 2020-06-19 TW TW109120821A patent/TW202115074A/zh unknown
- 2020-06-19 WO PCT/EP2020/067082 patent/WO2020254565A1/en active Application Filing
- 2020-06-19 PL PL20734871.5T patent/PL3986897T3/pl unknown
- 2020-06-19 AR ARP200101747A patent/AR119208A1/es unknown
- 2020-06-19 AU AU2020295703A patent/AU2020295703A1/en active Pending
- 2020-06-19 PE PE2021002089A patent/PE20220576A1/es unknown
- 2020-06-19 EP EP20734348.4A patent/EP3986896B1/en active Active
- 2020-06-19 JP JP2021576032A patent/JP2022538403A/ja active Pending
- 2020-06-19 JP JP2021576031A patent/JP2022538055A/ja active Pending
- 2020-06-19 HR HRP20231276TT patent/HRP20231276T1/hr unknown
- 2020-06-19 CN CN202080044300.3A patent/CN114008049A/zh active Pending
- 2020-06-19 MX MX2021015464A patent/MX2021015464A/es unknown
- 2020-06-19 MA MA56508A patent/MA56508B1/fr unknown
- 2020-06-19 CN CN202080044011.3A patent/CN113993872A/zh active Pending
- 2020-06-19 HU HUE20734871A patent/HUE063676T2/hu unknown
- 2020-06-19 US US17/620,239 patent/US20220315592A1/en active Pending
- 2020-06-19 WO PCT/EP2020/067086 patent/WO2020254568A1/en active Application Filing
- 2020-06-19 JP JP2021575205A patent/JP2022537191A/ja active Pending
-
2021
- 2021-11-29 IL IL288522A patent/IL288522A/en unknown
- 2021-12-15 CO CONC2021/0017173A patent/CO2021017173A2/es unknown
- 2021-12-20 CL CL2021003408A patent/CL2021003408A1/es unknown
- 2021-12-21 US US17/558,053 patent/US20220135571A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NZ766835A (en) | Pharmaceutical compounds | |
EP2477987B1 (en) | Modulators of toll-like receptors | |
GEP20217242B (en) | Pyrazolo[1,5-a]pyrazin-4-yl derivatives as jak-inhibitors | |
NZ601754A (en) | Pyrrolopyrimidine compounds as inhibitors of cdk4/6 | |
RU2018119295A (ru) | Фармацевтические составы для местного применения для лечения связанных с воспалением состояний | |
MX2020001218A (es) | Inhibidores selectivos de inflamasoma nlrp3. | |
GEP20156417B (en) | Pyrrolo [2,3-d] pyrimidine derivatives as inhibitors of tropomyosin-related kinases | |
WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
EA201290237A1 (ru) | Киназные ингибиторы | |
PH12020551639A1 (en) | Pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives as selective inhibitor of cyclin dependent kinase | |
PE20181888A1 (es) | Formulaciones liquidas de (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirrolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroxipirrolidina-1-carboxamida | |
HRP20221495T1 (hr) | Farmaceutske kompozicije koje sadrže derivate imidazotiadiazola i imidazopiridazina kao inhibitore proteazom aktiviranih receptora 4 (par4) za liječenje agregacije trombocita | |
BR112013014184A2 (pt) | compostos de triazina [1,2,4] triazolo [4,3-b][1,2,4], método de preparo e seu uso | |
WO2011113802A3 (en) | Imidazopyridine and purine compounds, compositions and methods of use | |
PH12020551638A1 (en) | Pharmaceutically active pyrazolo-triazine and/or pyrazolo-pyrimidine derivatives | |
HRP20231276T1 (hr) | Inhibitor egfr-a za liječenje raka | |
MX2015012091A (es) | Derivados de 2-((4-amino-3-(3-fluoro-5-hidroxifenil)-1h-pirazolo[3 ,4-d]pirimidin-1-il)metil)-3-(2-(trifluorometil)bencil)quinazolin -4(3h)-ona y su uso como inhibidores de fosfoinositida 3-quinasa. | |
HRP20160495T1 (hr) | Morfolinilbenzotriazini za uporabu u terapiji raka | |
MX2009010165A (es) | Nuevas imidazo[4,5-b]piridina-7-carboxamidas 704. | |
HRP20150030T1 (hr) | Derivati pirazolokinolina kao inhibitori dna-pk | |
NZ730189A (en) | Pharmaceutical formulations, processes, solid forms and methods of use relating to 1-ethyl-7-(2-methyl-6-(1h-1,2,4-triazol-3-yl)pyridin-3-yl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1h)-one | |
NZ703152A (en) | Dosing regimen for janus kinase (jak) inhibitors | |
NZ754944A (en) | Imidazo [1,5-a] pyrazine derivatives as pi3kdelta inhibitors | |
MX2018004517A (es) | Derivados de 6-[5-amino-6-(2-etoxietoxi)-imidazo[4,5-b]piridin-3-i l]nicotinonitrilo y su uso como inhibidores de cinasas asociadas al receptor de interleucina-1 (irak). | |
EA202190036A1 (ru) | Кристаллическая форма соединения для ингибирования активности cdk4/6 и ее применение |